Comments
Pharma major Cadila Healthcare Ltd (Zydus Cadila) on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) to market anti-diabetic drugs called Glyburide and Metformin Hcl tablets USP.
The drug falls in the anti-diabetic segment and the group’s formulations manufacturing site at Baddi in Himachal Pradesh will produce it for the US market.
The group now has 103 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in 2003-04, the company said in a statement here.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.